Chembio Diagnostics

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.

HAUPPAUGE, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2022 after the close of trading on Thursday, August 4, 2022.

Chembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022

Initiates distribution of SCoV-2 Ag Detect Self-Test to consumers in the United States and expansion of SURE CHECK HIV Self-Test distribution to consumers in Brazil and the United Kingdom Initiates distribution of SCoV-2 Ag Detect Self-Test to consumers in the United States and expansion of SURE CHECK HIV Self-Test distribution to consumers in Brazil and the United Kingdom

Chembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial Channel

Enservco

VistaGen Therapeutics

Which penny stocks are you watching in June? The post Hot Penny Stocks For Your Buy List This Month?

Hot Penny Stocks For Your Buy List This Month? 3 to Watch

HAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the election of Leslie Teso-Lichtman to its Board of Directors at Chembio's 2022 Annual Meeting of Stockholders.

Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors

HAUPPAUGE, N.Y., May 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has entered into a manufacturing agreement with Reszon Diagnostics International Sdn. Bhd. (Reszon) to produce Chembio's HIV 1/2 STAT-PAK Assay products in the Chembio Diagnostics Malaysia (CDM) facility. CDM had previously suspended operations in May 2020.

Chembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio's HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia Facility

Chembio Diagnostics, Inc. (NASDAQ:CEMI ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Rick Eberly - President & Chief Executive Officer Larry Steenvoorden - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Per Ostlund - Craig Hallum Joanne Lee - Maxim Group Operator Good day, ladies and gentlemen, and welcome to the Chembio First Quarter 2022 Earnings Conference Call and Webcast. At this time, all participants have been placed on a listen-only mode and the floor will be open for questions and comments after the presentation.

Chembio Diagnostics, Inc. (CEMI) CEO Rick Eberly on Q1 2022 Results - Earnings Call Transcript

HAUPPAUGE, N.Y., May 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2022.

Chembio Diagnostics Reports First Quarter 2022 Financial Results

HAUPPAUGE, N.Y., April 21, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 5, 2022.

Chembio Diagnostics to Report First Quarter 2022 Financial Results on May 5, 2022

Chembio Diagnostics Inc's (NASDAQ: CEMI) Q4 sales increased 101% Y/Y to $20.6 million, beating the consensus of $13.55 million. Net product sales increased 154% to $17.4 million.

Despite More Than Double Q4 Sales, Chembio Diagnostics Posts Deeper Losses

Chembio Diagnostics Inc (NASDAQ: CEMI) shares are trading lower by 12.4% at $0.81 after the company reported worse-than-expected fourth-quarter adjusted EPS results. Chembio Diagnostics reported quarterly losses of 32 cents per share which missed the analyst consensus estimate of a.

Why Chembio Diagnostics Shares Are Falling

Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q4 2021 Results - Earnings Call Transcript

HAUPPAUGE, N.Y., March 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2021.

Chembio Diagnostics Reports Fourth Quarter and Full Year 2021 Financial Results

HAUPPAUGE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today reported that, in accordance with Nasdaq Listing Rule 5635(c)(4), it has granted a nonqualified stock option and a restricted stock unit award to Lawrence J. Steenvoorden, Chembio's new Chief Financial Officer and Executive Vice President, outside of any stock equity plan. The awards were granted upon Mr. Steenvoorden's joining Chembio on January 5, 2022, in accordance with terms of his employment agreement with Chembio, which was entered into on December 30, 2021 and became effective as of January 5, 2022.

Chembio Diagnostics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

HAUPPAUGE, N.Y., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment of Larry Steenvoorden as Chief Financial Officer effective immediately.

Chembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial Officer

Chembio Diagnostics Inc's (NASDAQ: CEMI) said that on December 1, it received an FDA notice for additional data related to Clinical Laboratory Improvement Amendment (CLIA) waiver submission for the DPP HIV-Syphilis test system.  In the SEC filing, the Company notes that seeking additional data will extend, for a currently undeterminable period, the process for seeking a CLIA waiver for the DPP HIV-Syphilis test system.

FDA Asks Chembio Additional Data On HIV-Syphilis Test For CLIA Waiver

HAUPPAUGE, N.Y., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has submitted a De Novo/510(k) Request to the U.S. Food and Drug Administration (FDA) for the DPP SARS-CoV-2 Antigen test system.

Chembio Diagnostics Submits FDA De Novo/510(k) Request for DPP SARS-CoV-2 Antigen Test System

South Africa Health Products Regulatory Authority (SAHPRA) has approved Chembio Diagnostics Inc's (NASDAQ:CEMI) DPP SARS-CoV-2 Antigen test for use at the point of care. The DPP SARS-CoV-2 Antigen test has been designed to detect SARS-CoV-2 antigens in only 20 minutes.

Chembio Diagnostics' DPP COVID-19 Antigen Test Approved In South Africa

The stock price of Chembio Diagnostics Inc (NASDAQ: CEMI) increased by over 15% pre-market today. This is why it happened.

Chembio Diagnostics (CEMI) Stock: Why The Price Jumped Today

Geovax Labs

iBio

NovaBay Pharmaceuticals

Oragenics

SINTX Technologies Inc

XpresSpa Group

Hot penny stocks to watch as new virus fears emerge on Black Friday. The post Hot Penny Stocks To Buy?

Hot Penny Stocks To Buy? 7 To Watch As African Variant Shakes Markets

Chembio Diagnostics Inc (NASDAQ:CEMI) submitted an Emergency Use Authorization (EUA) application to the FDA for the new DPP SARS-CoV-2 Antigen test. The DPP SARS-CoV-2 Antigen test system has been designed to detect COVID-19 antigens in 20 minutes.

Chembio Files For FDA Emergency Use Nod For COVID-19 Antigen Test

HAUPPAUGE, N.Y., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test.

Chembio Diagnostics Submits EUA Application for New DPP SARS-CoV-2 Antigen Test

Chembio Diagnostics, Inc. (CEMI) CEO Richard Eberly on Q2 2021 Results - Earnings Call Transcript

HAUPPAUGE, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2021 after the close of trading on Thursday, November 4, 2021.

Chembio Diagnostics to Report Third Quarter 2021 Financial Results on November 4, 2021

Test Provides Simultaneous Detection of Flu A, Flu B, and SARS-CoV-2 Test Provides Simultaneous Detection of Flu A, Flu B, and SARS-CoV-2

Chembio Announces EUA Submission for DPP Respiratory Antigen Panel

Sphere 3D

Exela Technologies

Trading penny stocks in September? You need to know these 3 things The post Investing in Penny Stocks in September?

News for Chembio Diagnostics Stock (CEMI)